<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Echo Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Echo Res Pract</journal-id><journal-title-group><journal-title>Echo Research and Practice</journal-title></journal-title-group><issn pub-type="epub">2055-0464</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863394</article-id><article-id pub-id-type="publisher-id">73</article-id><article-id pub-id-type="doi">10.1186/s44156-025-00073-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Assessment of myocardial work in sarcomere gene mutation carriers, healthy controls and overt nonobstructive hypertrophic cardiomyopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pires</surname><given-names>Carla Marques</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Joy</surname><given-names>George</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Triantafyllou</surname><given-names>Miltiadis</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>Ricardo Prista</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Savvatis</surname><given-names>Konstantinos</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lopes</surname><given-names>Luis Rocha</given-names></name><address><email>luis.lopes.10@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jjy0g33</institution-id><institution-id institution-id-type="GRID">grid.436922.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 4655 1975</institution-id><institution>Department of Cardiology, </institution><institution>Braga Hospital, </institution></institution-wrap>Braga, Portugal </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00nh9x179</institution-id><institution-id institution-id-type="GRID">grid.416353.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 9244 0345</institution-id><institution>Barts Heart Center, St Bartholomew&#x02019;s Hospital, Barts Health NHS Trust, </institution></institution-wrap>London, England </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Institute of Cardiovascular Science, </institution><institution>University College London, </institution></institution-wrap>London, England </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04faw9m73</institution-id><institution-id institution-id-type="GRID">grid.413537.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0540 7520</institution-id><institution>Halmstad Hospital, </institution></institution-wrap>Region Halland, Halmstad, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>5</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hypertrophic cardiomyopathy (HCM) is defined by unexplained hypertrophy and often characterized by diastolic and systolic dysfunction. HCM patients are known to have impaired left ventricular (LV) myocardial work (MW), a more load-independent parameter compared to global longitudinal strain (GLS). We hypothesized that impaired MW might occur in sarcomere mutation carriers without LV hypertrophy.</p></sec><sec><title>Methods and results</title><p id="Par2">A single centre study with a case-control design. Patients with overt nonobstructive HCM and a causal sarcomere gene variant (<italic>n</italic>&#x02009;=&#x02009;44), carriers (<italic>n</italic>&#x02009;=&#x02009;51) and age and sex matched (to the carriers) healthy controls (<italic>n</italic>&#x02009;=&#x02009;32) underwent a transthoracic echocardiogram including myocardial deformation analysis to calculate GLS and MW. Global work index (GWI) (1695&#x02009;&#x000b1;&#x02009;332mmHg% vs. 1881.50&#x02009;&#x000b1;&#x02009;490mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.001) and global constructive work (GCW) (2017.78&#x02009;&#x000b1;&#x02009;323.05mmHg% vs. 2329.31&#x02009;&#x000b1;&#x02009;485.44 mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.002) were lower in sarcomere mutation carriers compared to controls. LV ejection fraction and GLS were similar between these two groups. GWI (1209&#x02009;&#x000b1;&#x02009;735mmHg% vs. 1695&#x02009;&#x000b1;&#x02009;332mmhg%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), GCW (1456&#x02009;&#x000b1;&#x02009;703mmHg% vs. 1993&#x02009;&#x000b1;&#x02009;389mmHg%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), global wasted work (GWW) (117&#x02009;&#x000b1;&#x02009;148mmHg% vs. 96&#x02009;&#x000b1;&#x02009;69mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.006) and global work efficiency (GWE) (89&#x02009;&#x000b1;&#x02009;7% vs. 95&#x02009;&#x000b1;&#x02009;3%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001)] were worse in overt non-obstructive HCM patients.</p></sec><sec><title>Conclusion</title><p id="Par3">We show for the first time that MW indexes were significantly worse in sarcomere mutation carriers compared to controls, suggesting that MW is more sensitive to early changes than GLS and could have a significant role in the evaluation and follow-up of carriers.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nonobstructive hypertrophic cardiomyopathy</kwd><kwd>Carriers</kwd><kwd>Myocardial work</kwd><kwd>Sarcomere mutations</kwd></kwd-group><funding-group><award-group><funding-source><institution>British Heart Foundation clinical research training fellowship</institution></funding-source><award-id>FS/CRTF/21/2469</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Barts Charity project grant</institution></funding-source><award-id>MRC0281</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Medical Research Council UK Research and Innovation Clinical Academic Research Partnership award</institution></funding-source><award-id>MR/T005181/1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; British Society of Echocardiography 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Hypertrophic cardiomyopathy (HCM) is a myocardial disease defined by left ventricle hypertrophy (LVH) in any myocardial segment, that is not solely explained by abnormal loading conditions [<xref ref-type="bibr" rid="CR1">1</xref>]. </p><p id="Par5">In up to 40% of cases, a pathogenic or likely pathogenic sarcomeric gene variant is identified. In most cases, this disease is inherited as an autosomal dominant trait. The two most common causal genes are &#x003b2;-Myosin Heavy chain (<italic>MYH7</italic>) and Myosin-binding Protein C (<italic>MYBPC3</italic>), identified in 70% of genotype-positive patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. </p><p id="Par6">HCM is characterized by distinctive myocardial histological changes: myocyte hypertrophy, myofibrillar disarray, microvascular dysplasia and myocardial fibrosis. These ultimately lead to small and stiff ventricles with impaired diastolic and systolic function despite preserved ejection fraction (EF) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Previous studies described a reduced left ventricle (LV) global longitudinal strain (GLS) despite normal or supranormal EF, reflecting the presence of systolic dysfunction due to impaired longitudinal function [<xref ref-type="bibr" rid="CR4">4</xref>]. Additionally, abnormal LV-GLS has been correlated with myocardial fibrosis and adverse composite cardiac outcomes [<xref ref-type="bibr" rid="CR5">5</xref>]. </p><p id="Par7">Nevertheless, GLS is an imperfect tool in this population due to pre and after-load dependency. Myocardial work (MW) is a more load-independent tool and a novel noninvasive approach to evaluate myocardial performance. MW integrates LV deformation and afterload by constructing a pressure-strain loop. Therefore, it enables investigation of LV performance in cases of changes in afterload, which could lead to misleading conclusions if relying solely on strain analysis [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Recent studies have shown that reduced MW in patients with overt HCM correlated with myocardial fibrosis and worst prognosis [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. </p><p id="Par8">Regarding sarcomere mutation carriers, male gender and electrocardiographic anomalies were associated with higher risk of developing overt HCM in recent work [<xref ref-type="bibr" rid="CR10">10</xref>]. In contrast, neither EF nor LV-GLS had clear prognostic value for the development of HCM during follow-up [<xref ref-type="bibr" rid="CR11">11</xref>]. </p><p id="Par9">MW was never studied in sarcomere mutation carriers. The aim of this study is to assess MW in this population and to compare it with healthy controls and overt HCM patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par10">This was a single-center study with a case-control design developed at the Inherited Cardiovascular Disease Unit, Barts Heart Center, St Bartholomew&#x02019;s Hospital, Barts Health NHS Trust. Ethical approval for the study was given by the Research Ethics Committee (IRAS 227168) and met the criteria established by the Declaration of Helsinki [<xref ref-type="bibr" rid="CR12">12</xref>]. All participants provided written informed consent.</p><p id="Par11">The study population comprised three groups: group 1 was composed of carriers of a likely pathogenic or pathogenic sarcomere gene variant; group 2 included patients with overt nonobstructive HCM (NOHCM) with a likely pathogenic or pathogenic sarcomere gene variant and group 3 were age and sex-matched (to the carriers) healthy controls. NOHCM was defined as peak Doppler LV outflow tract gradient of &#x0003c;&#x02009;30 mmHg, at rest and Valsalva [<xref ref-type="bibr" rid="CR1">1</xref>]. </p><p id="Par12">Adult individuals with subclinical or overt HCM were prospectively recruited from databases for genotyped patients. Pathogenicity for detected variants was assessed using American College of Medical Genetics (ACMG) criteria [<xref ref-type="bibr" rid="CR13">13</xref>]. </p><p id="Par13">Inclusion criteria for the current study were as follows (i) overt NOHCM were diagnosed as per the guidelines (myocardial wall thickness equal or greater than 15&#x000a0;mm in any cardiac segment by any imaging modality or equal or greater than 13&#x000a0;mm in individuals with a first degree relative with confirmed HCM); [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] (ii) subclinical HCM (Genotype&#x02009;+&#x02009;LVH-) were individuals with pathogenic/likely pathogenic variants confirmed on cascade screening but with myocardial wall thickness less than 13&#x000a0;mm; (iii) healthy volunteers with no relevant past medical history or risk factors for coronary disease were prospectively matched for age and sex to the subclinical HCM (Genotype&#x02009;+&#x02009;LVH-) cohort.</p></sec></sec><sec id="Sec4"><title>Echocardiography</title><p id="Par14">All participants underwent a transthoracic echocardiogram including myocardial deformation analysis to calculate GLS and MW.</p><p id="Par15">LV measurements and left atrium (LA) measurements were routinely obtained. Measurements of mitral inflow (E wave-early diastolic wave and A wave-late diastolic wave) and e&#x02032; velocity were obtained from the apical 4-chamber view using pulsed-wave Doppler (PWD) and tissue Doppler imaging (TDI), respectively. LVEF was calculated using biplane Simpson&#x02019;s rule [<xref ref-type="bibr" rid="CR14">14</xref>]. LV GLS and MW were measured using the speckle tracking technique.</p><p id="Par16">The same investigator, blinded to case-control status, reviewed the images, and performed offline myocardial deformation analysis in all study subjects.</p><p id="Par17">The offline analysis was done on <italic>EchoPac</italic> V203 (<italic>General Electric</italic><sup>&#x000ae;</sup><italic>Healthcare</italic>). Two-dimensional LV images from apical four, two and three-chambers were acquired with frame rates between 40 and 80 frames/s. The software automatically outlined the LV endocardium and the tracking was carefully observed and manually adjusted when necessary. Similarly, to previous studies [<xref ref-type="bibr" rid="CR6">6</xref>], non-invasive brachial artery blood pressure evaluation was used to replace LV systolic pressure. This measurement was performed in the same-day, prior to the realization of the transthoracic echocardiogram. A pressure-strain loop (PSL) and resultant MW parameters were automatically obtained.</p><p id="Par18">Global work index (GWI) reflected the MW performed by the LV during systole and was the area of PSL from mitral valve closure to mitral valve opening. Global constructive work (GCW) was the MW used for shortening (positive work) during systole and lengthening (negative work) during isovolumetric relaxation. Global wasted work (GWW) was the MW used for lengthening (negative work) during systole and shortening (positive work) during isovolumetric relaxation. Finally, global work efficiency (GWE) was the ratio between GCW and total MW (sum of GCW and GWW).</p><sec id="Sec5"><title>Statistical analysis</title><p id="Par19">Continuous variables were tested for normality using Kolmogorov-Smirnov&#x02019;s test. Measures of central tendency (mean or median) and dispersion (standard deviation or interquartile range) were chosen according to normality test result. To examine differences between groups in normality distributed variables the t-student test or Welsh test (if homogeneity of variances was not assumed) was used. In non-normality distributed variables, Mann&#x02013;Whitney test was performed. Categorical variables were expressed as relative and absolute frequencies and compared using the Chi-square test (&#x003c7;2) or Fisher&#x02019;s test.</p><p id="Par20">All analyses used <italic>IBM SPSS</italic><sup>&#x000ae;</sup> (version 26; <italic>IBM corp.</italic>,<italic> Armonk</italic>,<italic> NY</italic>). Statistical significance was defined when <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec6"><title>RESULTS</title><p id="Par21">This study included 95 patients with a likely pathogenic or pathogenic sarcomere gene variant: 51 carriers (group 1) and 44 with overt NOHCM (group 2). Baseline characteristics of study subjects are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par22">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline clinical data of group 1 and group 2 participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">G1: Carriers<break/><italic>n</italic>&#x02009;=&#x02009;51</th><th align="left">G2: Overt NOHCM<break/><italic>n</italic>&#x02009;=&#x02009;44</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4">
<bold>Baseline features</bold>
</td></tr><tr><td align="left">Age, years, mean (SD)</td><td char="." align="char">39.29 (11.86)</td><td char="." align="char">52.04 (13.32)</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Female, n (%)</td><td char="." align="char">30.00 (58.82)</td><td char="." align="char">17.00 (33.33)</td><td char="." align="char">0.01</td></tr><tr><td align="left">BMI, kg/m2, median (IQ)</td><td char="." align="char">23.56 (6.48)</td><td char="." align="char">25.78 (7.15)</td><td char="." align="char">0.004</td></tr><tr><td align="left">BSA, mean (SD)</td><td char="." align="char">1.85 (0.20)</td><td char="." align="char">1.98 (0.24)</td><td char="." align="char">0.005</td></tr><tr><td align="left">Sarcomere gene variant, n (%)</td><td align="left"/><td align="left"/><td char="." align="char" rowspan="4">0.581</td></tr><tr><td align="left">
<italic>MYBPC3</italic>
</td><td char="." align="char">31.00 (60.78)</td><td char="." align="char">36.00 (70.59)</td></tr><tr><td align="left">
<italic>MYH7</italic>
</td><td char="." align="char">12.00 (23.53)</td><td char="." align="char">9.00 (17.65)</td></tr><tr><td align="left">Other</td><td char="." align="char">8.00 (15.69)</td><td char="." align="char">6.00 (11.76)</td></tr><tr><td align="left">Family history of sudden death, n(%)</td><td char="." align="char">27.00 (52.94)</td><td char="." align="char">19.00 (37.25)</td><td char="." align="char">0.108</td></tr><tr><td align="left">Arterial hypertension, n(%)</td><td char="." align="char">5.00 (9.80)</td><td char="." align="char">21.00 (41.18)</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Diabetes, n (%)</td><td char="." align="char">1.00 (1.96)</td><td char="." align="char">8.00 (15.69)</td><td char="." align="char">0.015</td></tr><tr><td align="left">Dyslipidemia, n (%)</td><td char="." align="char">4.00 (7.84)</td><td char="." align="char">15.00 (29.41)</td><td char="." align="char">0.005</td></tr><tr><td align="left">Smoking, n(%)</td><td char="." align="char">5.00 (9.80)</td><td char="." align="char">8.00 (15.69)</td><td char="." align="char">0.353</td></tr><tr><td align="left">Other cardiac disease, n(%)</td><td char="." align="char">4.00 (7.84)</td><td char="." align="char">8.00 (15.69)</td><td char="." align="char">0.218</td></tr></tbody></table><table-wrap-foot><p>BMI: Body mass index; BSA: Body surface area; IQ: Interquartile Range; <italic>MYBPC3</italic>: Cardiac myosin-binding protein C3; <italic>MYH7</italic>: myosin heavy chain 7; NOHCM: Nonobstructive hypertrophic cardiomyopathy, SD: standard deviation</p></table-wrap-foot></table-wrap>
</p><p id="Par23">Compared with carriers, overt NOHCM patients were older, had a lower prevalence of female gender, higher values of body mass index and a higher prevalence of cardiovascular risk factors. We found no significant differences regarding family history of sudden death. <italic>MYBPC3</italic> was the most frequent causal gene in both groups.</p><p id="Par24">Regarding transthoracic echocardiogram evaluation (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) patients with overt NOHCM had higher values of E/e&#x02019; ratio and lower values of MAPSE. LV dimensions, TAPSE and LVEF did not differ significantly between groups.</p><p id="Par25">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Echocardiographic features of group 1 and group 2 participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">G1: Carriers<break/><italic>n</italic>&#x02009;=&#x02009;51</th><th align="left">G2: Overt NOHCM<break/><italic>n</italic>&#x02009;=&#x02009;44</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4">
<bold>Transthoracic echocardiogram: routine evaluation</bold>
</td></tr><tr><td align="left">EDLVD, mm, median (IQ)</td><td char="." align="char">44.00 (8.00)</td><td char="." align="char">44.30 (7.60)</td><td align="left">0.274</td></tr><tr><td align="left">ESLVD, mm, median (IQ)</td><td char="." align="char">28.85 (7.00)</td><td char="." align="char">29.75 (7.70)</td><td align="left">0.962</td></tr><tr><td align="left">MWT, mm, median (IQ)</td><td char="." align="char">10.00 (2.00)</td><td char="." align="char">17.00 (3.00)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td align="left">LA diameter, mm, median (IQ)</td><td char="." align="char">33.00 (6.00)</td><td char="." align="char">42.50 (6.00)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">LA area, cm&#x000b2;, median (IQ)</td><td char="." align="char">18.00 (5.30)</td><td char="." align="char">23.60 (8.10)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">LA volume/BSA, ml/m&#x000b2;, median (IQ)</td><td char="." align="char">24.32 (12.94)</td><td char="." align="char">37.47 (22.64)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">LVEF, %, mean (SD)</td><td char="." align="char">59.76 (5.11)</td><td char="." align="char">61.07 (8.62)</td><td align="left">0.381</td></tr><tr><td align="left">MAPSE, mm, median (IQ)</td><td char="." align="char">14.50 (3.00)</td><td char="." align="char">9.10 (4.30)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">TAPSE, mm, mean (SD)</td><td char="." align="char">23.34 (4.05)</td><td char="." align="char">22.08 (5.43)</td><td align="left">0.198</td></tr><tr><td align="left">E/e&#x02019;, median (IQ)</td><td char="." align="char">5.85 (2.48)</td><td char="." align="char">8.62 (4.66)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Blood pressure</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Systolic arterial BP, mmHg, median (IQ)</td><td char="." align="char">115.00 (20.00)</td><td char="." align="char">120.50 (24.00)</td><td align="left">0.017</td></tr><tr><td align="left">Diastolic arterial BP, mmHg, median (IQ)</td><td char="." align="char">70.00 (12.00)</td><td char="." align="char">73.50 (12.00)</td><td align="left">0.110</td></tr><tr><td align="left">
<bold>Myocardial deformation analysis</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">GWI, mmHg%, median (IQ)</td><td char="." align="char">1695.00 (332.00)</td><td char="." align="char">1229 0.50 (474.64)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">GCW, mmHg%, mean (SD)</td><td char="." align="char">2017.78 (323.05)</td><td char="." align="char">1545.08 (537.71)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">GWW, mmHg%, median (IQ)</td><td char="." align="char">96.00 (69.00)</td><td char="." align="char">116.00 (158.00)</td><td align="left">0.028</td></tr><tr><td align="left">GWE, %, median (IQ)</td><td char="." align="char">95.00 (3.00)</td><td char="." align="char">89.00 (8.00)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">GLS, %, median (IQ)</td><td char="." align="char">-18.00 (3.00)</td><td char="." align="char">-13.00 (4.00)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p>BSA: Body surface area; BP: Blood pressure; EDLVD: end-diastolic left ventricular diameter; ESLVD: end-systolic left ventricular diameter; IQ: interquartile range; GWI: Global work index; GCW: Global constructive work; GWW: Global wasted work; GWE: Global work efficiency; GLS: Global longitudinal strain; LA: Left atrium; LVEF: left ventricle ejection fraction; MAPSE: mitral annular plane systolic excursion; MWT: Maximum wall thickness; NOHCM: Nonobstructive hypertrophic cardiomyopathy, SD: standard deviation, TAPSE: tricuspid annular plane systolic excursion</p></table-wrap-foot></table-wrap>
</p><p id="Par26">Myocardial deformation analysis revealed that LVGLS and all MW indexes (GWI: 1230vs1695mmHg%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; GCW 1545vs2018mmHg%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, GWW 116vs96mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.028; GWE 89vs95%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) were significantly worse in overt NOHCM patients (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A, B, <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par27">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Representative example of myocardial work parameter plot and pressure-strain loop in one mutation carrier (1&#x000a0;<bold>A</bold>) and one patient with overt nonobstructive hypertrophic cardiomyopathy (1<bold>B</bold>)</p></caption><graphic xlink:href="44156_2025_73_Fig1_HTML" id="d33e836"/></fig>
</p><p id="Par28">Further description of echocardiographic features is presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par29">Baseline demographic characteristics of the controls are presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par30">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Baseline clinical data of group 1 and group 3 participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">G1: Carriers<break/><italic>n</italic>&#x02009;=&#x02009;51</th><th align="left">G3: controls<break/><italic>n</italic>&#x02009;=&#x02009;32</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4">
<bold>Baseline features</bold>
</td></tr><tr><td align="left">Age, years, mean (SD)</td><td char="." align="char">39.29 (11.86)</td><td char="." align="char">41.69 (15.00)</td><td char="." align="char">0.447</td></tr><tr><td align="left">Female, n (%)</td><td char="." align="char">30.00 (58.82)</td><td char="." align="char">18.00 (56.25)</td><td char="." align="char">0.817</td></tr><tr><td align="left">BSA, mean (SD)</td><td char="." align="char">1.85 (0.20)</td><td char="." align="char">1.87 (0.25)</td><td char="." align="char">0.708</td></tr></tbody></table><table-wrap-foot><p>BSA: Body surface area; SD: standard deviation</p></table-wrap-foot></table-wrap>
</p><p id="Par31">There were no differences regarding LVEF, E/e&#x02019; ratio and LVGLS between carriers and controls. However, carriers had significantly lower values of GWI (1695vs1882mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.001) and GCW (2018vs2329mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.002) - Fig. <xref rid="Fig2" ref-type="fig">2</xref>.</p><p id="Par32">Further description of echocardiographic features is presented in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par33">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Echocardiographic features of group 1 and group 3 participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">G1: Carriers<break/><italic>n</italic>&#x02009;=&#x02009;51</th><th align="left">G3: Controls<break/><italic>n</italic>&#x02009;=&#x02009;32</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4">
<bold>Transthoracic echocardiogram</bold>
</td></tr><tr><td align="left">EDLVD, mm, median (IQ)</td><td char="." align="char">44.00 (8.00)</td><td char="." align="char">51.50 (7.80)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">ESLVD, mm, mean (SD)</td><td char="." align="char">28.66 (4.36)</td><td char="." align="char">33.25 (4.47)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">LA area, cm&#x000b2;, mean (SD)</td><td char="." align="char">17.72 (4.33)</td><td char="." align="char">18.56 (3.51)</td><td align="left">0.360</td></tr><tr><td align="left">2D LVEF, %, mean (SD)</td><td char="." align="char">59.76 (5.11)</td><td char="." align="char">58.81 (3.69)</td><td align="left">0.960</td></tr><tr><td align="left">E/e&#x02019;, median (IQ)</td><td char="." align="char">5.86 (2.00)</td><td char="." align="char">5.68 (2.00)</td><td align="left">0.244</td></tr><tr><td align="left">
<bold>Blood pressure</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Systolic arterial BP, mmHg, median (IQ)</td><td char="." align="char">115.00 (20.00)</td><td char="." align="char">123.00 (26.00)</td><td align="left">0.09</td></tr><tr><td align="left">Diastolic arterial BP, mmHg, median (IQ)</td><td char="." align="char">70.00 (12.00)</td><td char="." align="char">74.50 (14.00)</td><td align="left">0.101</td></tr><tr><td align="left">
<bold>Myocardial deformation analysis</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">GWI, mmHg%, median (IQ)</td><td char="." align="char">1695.00 (332.00)</td><td char="." align="char">1881.50 (490.00)</td><td align="left">0.001</td></tr><tr><td align="left">GCW, mmHg%, mean (SD)</td><td char="." align="char">2017.78 (323.05)</td><td char="." align="char">2329.31 (485.44)</td><td align="left">0.002</td></tr><tr><td align="left">GWW, mmHg%, median (IQ)</td><td char="." align="char">96.00 (69.00)</td><td char="." align="char">81.50 (43.00)</td><td align="left">0.457</td></tr><tr><td align="left">GWE, %, median (IQ)</td><td char="." align="char">95.00 (3.00)</td><td char="." align="char">96.00 (2.00)</td><td align="left">0.177</td></tr><tr><td align="left">GLS, %, median (IQ)</td><td char="." align="char">-18.00 (3.00)</td><td char="." align="char">-18.45 (2.60)</td><td align="left">0.256</td></tr></tbody></table><table-wrap-foot><p>BP: Blood pressure; EDLVD: end-diastolic left ventricular diameter; ESLVD: end-systolic left ventricular diameter; IQ: interquartile range; GWI: Global work index; GCW: Global constructive work; GWW: Global wasted work; GWE: Global work efficiency; GLS: Global longitudinal strain; LA: Left atrium; LVEF: left ventricle ejection fraction, SD: standard deviation</p></table-wrap-foot></table-wrap>
</p><p id="Par34">Patients with <italic>MYBPC3 </italic><italic>vs </italic><italic>MYH7</italic> gene variants did not have significantly different MW indexes and LVGLS in subclinical (GWI: 1689vs1753mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.623; GCW 2027vs2057mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.844, GWW 103vs86mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.277; GWE 95vs96%, <italic>p</italic>&#x02009;=&#x02009;0.314) or overt NOHCM (GWI: 1225vs1249mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.901; GCW 1556vs1498mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.783, GWW 116vs141mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.959; GWE 91vs88%, <italic>p</italic>&#x02009;=&#x02009;0.401) (Tables&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref>).</p><p id="Par35">
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Myocardial deformation analysis stratified by sarcomere gene in group 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Carriers with <italic>MYBPC3</italic><break/><italic>n</italic>&#x02009;=&#x02009;31</th><th align="left">Carriers with <italic>MYH7</italic><break/><italic>n</italic>&#x02009;=&#x02009;12</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">
<bold>Blood pressure</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Systolic arterial BP, mmHg, mean (SD)</td><td char="." align="char">117.61 (15.22)</td><td char="." align="char">118.83 (19.24)</td><td char="." align="char">0.846</td></tr><tr><td align="left">Diastolic arterial BP, mmHg, median (IQ)</td><td char="." align="char">70.00 (15.00)</td><td char="." align="char">70.00 (11.00)</td><td char="." align="char">0.530</td></tr><tr><td align="left">
<bold>Myocardial deformation analysis</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">GWI, mmHg%, mean (SD)</td><td char="." align="char">1689.13 (239.38)</td><td char="." align="char">1753.17 (415.30)</td><td char="." align="char">0.623</td></tr><tr><td align="left">GCW, mmHg%, mean (SD)</td><td char="." align="char">2027.03 (280.34)</td><td char="." align="char">2056.83 (483.14)</td><td char="." align="char">0.844</td></tr><tr><td align="left">GWW, mmHg%, median (IQ)</td><td char="." align="char">103.13 (49.38)</td><td char="." align="char">85.58 (39.27)</td><td char="." align="char">0.277</td></tr><tr><td align="left">GWE, %, median (IQ)</td><td char="." align="char">95.00 (3)</td><td char="." align="char">95.50 (3)</td><td char="." align="char">0.314</td></tr><tr><td align="left">GLS, %, median (IQ)</td><td char="." align="char">-18.00 (2.00)</td><td char="." align="char">-18.50 (4.50)</td><td char="." align="char">0.565</td></tr></tbody></table><table-wrap-foot><p>BP: Blood pressure; IQ: interquartile range; GWI: Global work index; GCW: Global constructive work; GWW: Global wasted work; GWE: Global work efficiency; GLS: Global longitudinal strain, SD: standard deviation</p></table-wrap-foot></table-wrap>
</p><p id="Par36">
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Myocardial deformation analysis stratified bysarcomere gene in group 2 </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left">Overt NOHCM&#x02009;+&#x02009;MYBPC3<break/><italic>n</italic>&#x02009;=&#x02009;31</th><th align="left">Overt NOHCM&#x02009;+&#x02009;MYH7<break/><italic>n</italic>&#x02009;=&#x02009;8</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="2">
<bold>Blood pressure</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="2">Systolic arterial BP, mmHg, mean (SD)</td><td align="left">122.00 (20.00)</td><td align="left">119.00 (33.00)</td><td align="left">0.142</td></tr><tr><td align="left" colspan="2">Diastolic arterial BP, mmHg, mean (SD)</td><td align="left">75.45 (9.49)</td><td align="left">71.75 (8.91)</td><td align="left">0.326</td></tr><tr><td align="left">
<bold>Myocardial deformation analysis</bold>
</td><td align="left" colspan="2"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="2">GWI, mmHg%, mean (SD)</td><td align="left">1224.87 (456.91)</td><td align="left">1248.75 (571.27)</td><td align="left">0.901</td></tr><tr><td align="left" colspan="2">GCW, mmHg%, mean (SD)</td><td align="left">1555.97 (510.40)</td><td align="left">1497.75 (598.89)</td><td align="left">0.783</td></tr><tr><td align="left" colspan="2">GWW, mmHg%, median (IQ)</td><td align="left">116.00 (164.00)</td><td align="left">141.00 (170.00)</td><td align="left">0.959</td></tr><tr><td align="left" colspan="2">GWE, %, median (IQ)</td><td align="left">91.00 (8.00)</td><td align="left">88.00 (13.00)</td><td align="left">0.401</td></tr><tr><td align="left" colspan="2">GLS, %, mean (SD)</td><td align="left">-12.81 (3.24)</td><td align="left">-13.37 (4.75)</td><td align="left">0.691</td></tr></tbody></table><table-wrap-foot><p>BP: Blood pressure; IQ: interquartile range; GWI: Global work index; GCW: Global constructive work; GWW: Global wasted work; GWE: Global work efficiency; GLS: Global longitudinal strain, NOHCM: Nonobstructive hypertrophic cardiomyopathy, SD: standard deviation</p></table-wrap-foot></table-wrap>
</p><p id="Par37">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Box plot comparing GWI, GCW and GWW among participants of this study</p><p>GWI: Global work index; GCW: Global constructive work; GWW: Global wasted work</p></caption><graphic xlink:href="44156_2025_73_Fig2_HTML" id="d33e1411"/></fig>
</p><p id="Par38">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Box plot comparing GWE among participants of this study</p><p>GWE: Global work efficiency</p></caption><graphic xlink:href="44156_2025_73_Fig3_HTML" id="d33e1422"/></fig>
</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par39">The main goal of this study was to evaluate MW in sarcomere carriers for the first time and assess whether an abnormal MW is part of the constellation of findings characteristic of subclinical HCM in mutation carriers.</p><p id="Par40">HCM phenotype encompasses morphological and functional abnormalities beyond hypertrophy. Subclinical features occur early in carriers, including electrocardiographic abnormalities (e.g. repolarization changes), multiple myocardial crypts, hyperdynamic radial LV function but with lower GLS, long mitral leaflets and displacement of the papillary muscles [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. </p><p id="Par41">In our study, carriers had significantly worse MW indexes: lower values of GWI (1695&#x02009;&#x000b1;&#x02009;332mmHg% vs. 18881.50&#x02009;&#x000b1;&#x02009;490mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.001) and GCW (2017.78&#x02009;&#x000b1;&#x02009;323.05mmHg% vs. 2329.31&#x02009;&#x000b1;&#x02009;485.44 mmHg%, <italic>p</italic>&#x02009;=&#x02009;0.002). There were no differences of LVEF and LVGLS between carriers and controls [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par42">Recent studies assessed MW in overt HCM (<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>). Galli et al. [<xref ref-type="bibr" rid="CR8">8</xref>]. in 2019, evaluated 82 patients with non-obstructive HCM and found a significantly reduced GCW, which was associated with myocardial fibrosis assessed by cardiac magnetic resonance [<xref ref-type="bibr" rid="CR8">8</xref>]. In line with Russel et al. [<xref ref-type="bibr" rid="CR6">6</xref>], these authors suggested that abnormal MW indexes reflected changes in myocardial oxygen consumption and metabolism, secondary to disarray and microvascular dysfunction. These findings were also supported by Br&#x000e1;s et al. [<xref ref-type="bibr" rid="CR19">19</xref>] who have shown that MW was significantly correlated with the extent of ischemia in cardiac magnetic resonance, independently of left ventricular hypertrophy or fibrosis.</p><p id="Par43">Moreover, Gon&#x000e7;alves et al. [<xref ref-type="bibr" rid="CR20">20</xref>] in 2021, described that GCW and GWI were significantly correlated with late gadolinium enhancement and a cut-off less than or equal to 1550 mmHg% of GCW was associated with significant fibrosis on cardiac magnetic resonance with a sensitivity of 91% and a specificity of 76%. Furthermore, Hiemstra et al. [<xref ref-type="bibr" rid="CR9">9</xref>] demonstrated that in patients with non-obstructive HCM, a GCW greater than 1730 mmHg% was associated with better event-free survival.</p><p id="Par44">Our study suggests that MW is more sensitive to early changes than LVGLS. These findings could have a significant implication for the evaluation and follow-up of sarcomere mutation carriers, since one of the possible future applications of identifying early markers of the disease would be an optimized tailoring of relatives under follow-up.</p><p id="Par45">A possible explanation to our findings is that abnormal MW indexes in carriers reflect impaired myocardial perfusion and tissue changes (disarray) that occurs before LV hypertrophy development. Recent studies had already challenged the conventional view, in which perfusion defects would be only secondary to LV hypertrophy and subsequent extravascular compressive forces and elevated intraventricular pressures. Hughes et al. [<xref ref-type="bibr" rid="CR21">21</xref>] evaluated 50 individuals with genotype -positive and LVH-negative using perfusion mapping cardiac magnetic resonance and reported that myocardial perfusion reserve was lower in carriers with a subendocardial: subepicardial myocardial perfusion reserve gradient. Vigneault et al. [<xref ref-type="bibr" rid="CR22">22</xref>], in a feature-tracking cardiac magnetic resonance study, described that mutation carriers had higher circumferential transmural strain difference than healthy controls, reflecting underlying myocardial dysfunction before left ventricle hypertrophy. Joy et al. [<xref ref-type="bibr" rid="CR23">23</xref>], using diffusion tensor imaging, have shown that microstructural changes and microvascular disease occur in the absence of LV hypertrophy in sarcomere mutation carriers.</p><p id="Par46">In an era of emerging therapies with potential for disease modification, myocardial work could be tested as an early disease marker in future trials, to help select the individuals that would benefit most and also access the response to those therapies.</p><sec id="Sec8"><title>Limitations</title><p id="Par47">Our study is a single-center and single vendor study with case-control design and a relatively small sample. Larger studies with prospective design should be performed to assess the prognostic implications of our results, including in integration with other known markers of early disease, derived from ECG and cardiac magnetic resonance.</p><p id="Par48">In addition, participants of group 1 (overt NOHCM) have an asymmetrical hypertrophy which can impact strain and MW analysis since this algorithm assumes that LV wall thickness is equal across all myocardial segments. However, these parameters have already been used in multiple studies in patients with HCM [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Our main focus and novelty is the identification of early MW changes in carriers, where hypertrophy is not present.</p></sec></sec><sec id="Sec9"><title>Conclusion</title><p id="Par49">In summary, our study showed that MW is abnormal in HCM mutation carriers and part of the subclinical HCM phenotype.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>CMP and LRL designed the study. CMP performed statistical analysis and wrote the initial draft of the manuscript. RP, AF, GJ, KS and MT obtained echocardiographic and clinical data under KS and LRL supervision. All authors reviewed and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Dr Joy is funded by a British Heart Foundation clinical research training fellowship (FS/CRTF/21/2469) and has received funding from a Barts Charity project grant (MRC0281).</p><p>Dr Lopes was supported by a Medical Research Council UK Research and Innovation Clinical Academic Research Partnership award (MR/T005181/1) and is currently supported by an NIHR Development and Skills Enhancement Award.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">Ethical approval for the study was given by the Research Ethics Committee (IRAS 227168) and met the criteria established by the Declaration of Helsinki [<xref ref-type="bibr" rid="CR12">12</xref>]. All participants provided written informed consent.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Non applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">Dr Lopes has received speaker fees from BMS, Sanofi Genzyme and Alnylam and consulting fees from BMS and Novo Nordisk.</p></notes><notes id="FPar4"><title>Clinical trial number</title><p id="Par53">Not applicable.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>EF</term><def><p id="Par54">Ejection fraction</p></def></def-item><def-item><term>GLS</term><def><p id="Par55">Global longitudinal strain</p></def></def-item><def-item><term>GCW</term><def><p id="Par56">Global constructive work</p></def></def-item><def-item><term>GWE</term><def><p id="Par57">Global work efficiency</p></def></def-item><def-item><term>GWI</term><def><p id="Par58">Global work index</p></def></def-item><def-item><term>GWW</term><def><p id="Par59">Global wasted work</p></def></def-item><def-item><term>HCM</term><def><p id="Par60">Hypertrophic cardiomyopathy</p></def></def-item><def-item><term>LA</term><def><p id="Par61">Left atrium</p></def></def-item><def-item><term>LV</term><def><p id="Par62">Left ventricle</p></def></def-item><def-item><term>LVH</term><def><p id="Par63">Left ventricle hypertrophy</p></def></def-item><def-item><term>MAPSE</term><def><p id="Par64">Mitral annular plane systolic excursion</p></def></def-item><def-item><term>MYH7</term><def><p id="Par65">&#x003b2;-Myosin Heavy chain</p></def></def-item><def-item><term>MYBPC3</term><def><p id="Par66">Myosin-binding Protein C</p></def></def-item><def-item><term>MW</term><def><p id="Par67">Myocardial work</p></def></def-item><def-item><term>NOHCM</term><def><p id="Par68">Nonobstructive Hypertrophic cardiomyopathy</p></def></def-item><def-item><term>PSL</term><def><p id="Par69">Pressure-strain loop</p></def></def-item><def-item><term>PWD</term><def><p id="Par70">Pulsed-wave Doppler</p></def></def-item><def-item><term>TAPSE</term><def><p id="Par71">Tricuspid annular plane systolic excursion</p></def></def-item><def-item><term>TDI</term><def><p id="Par72">Doppler imaging</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Arbelo E, Protonotarios A, Gimeno JR et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Ommen SR, Mital S, Burke MA et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol. 2020;76(25).</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology. 2004;44.</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Serri K, Reant P, Lafitte M et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47(6).</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Tower-Rader A, Mohananey D, To A et al. Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature. JACC Cardiovasc Imaging. 2019;12(10).</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Russell K, Eriksen M, Aaberge L et al. A novel clinical method for quantification of regional left ventricular pressure-strain loop area: a non-invasive index of myocardial work. Eur Heart J. 2012;33(6).</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Manganaro R, Marchetta S, Dulgheru R et al. Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging. 2019;20(5).</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Galli E, Vitel E, Schnell F et al. Myocardial constructive work is impaired in hypertrophic cardiomyopathy and predicts left ventricular fibrosis. Echocardiography. 2019;36(1).</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Hiemstra YL, Van der Bijl P, Mahdiui M et al. Myocardial work in nonobstructive hypertrophic cardiomyopathy: implications for Outcome. J Am Soc Echocardiogr. 2020;33(10).</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Lorenzini M, Norrish G, Field E et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers. J Am Coll Cardiol. 2020;76(5).</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Van Velzen HG, Schinkel AFL, Van Grootel RWJ et al. Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes. Neth Hear J. 2019;27(3).</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20).</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5).</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Olivotto</surname><given-names>I</given-names></name><name><surname>Cecchi</surname><given-names>F</given-names></name><name><surname>Poggesi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Patterns of disease progression in hypertrophic cardiomyopathy an individualized approach to clinical staging</article-title><source>Circ Hear Fail</source><year>2012</year><volume>5</volume><issue>4</issue><fpage>535</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.112.967026</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal"> Olivotto I, Cecchi F, Poggesi C, et al. Patterns of disease progression in hypertrophic cardiomyopathy an individualized approach to clinical staging. Circ Hear Fail. 2012;5(4):535&#x02013;46.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Germans T, Wilde AAM, Dijkmans PA et al. Structural abnormalities of the Inferoseptal Left Ventricular Wall detected by Cardiac Magnetic Resonance Imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol. 2006;48(12).</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Groarke JD, Galazka PZ, Cirino AL et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur Heart J Cardiovasc Imaging. 2018;19(10).</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Joy G, Moon JC, Lopes LR. Detection of subclinical hypertrophic cardiomyopathy. Nat Rev Cardiol. 2023;20(6).</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Br&#x000e1;s PG, Rosa SA, Cardoso I et al. Microvascular dysfunction is associated with impaired myocardial work in obstructive and nonobstructive hypertrophic cardiomyopathy: a multimodality study. J Am Heart Assoc. 2023;12.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Gon&#x000e7;alves AV, Rosa SA, Branco L et al. Myocardial work is associated with significant left ventricular myocardial fibrosis in patients with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging [Internet]. 2021;37(7).</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Hughes RK, Camaioni C, Augusto JB et al. Myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers. J Am Heart Assoc. 2021;10(15).</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Vigneault DM, Yang E, Jensen PJ et al. Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: Cardiac MR Feature Tracking. Radiology. 2019;290(3).</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Joy G, Kelly CI, Webber M et al. Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and overt hypertrophic cardiomyopathy. Circulation. 2023;148(10).</mixed-citation></ref></ref-list></back></article>